65,437 trials
Diabetes
Primary: Percent of Self-Test Fingerstick Blood Glucose (BG) Results Within +/- 15mg/dL (<100mg/dL) and Within +/- 15% (>=100mg/dL) of Laboratory Glucose Method — 99.2 Percentage…
Smoking · Withdrawal Nicotine · ADHD
Primary: Brain Activity — 2.08; 2.01; 2.24; 2.30 z-score — p=0.46
Relapsing Multiple Sclerosis
Primary: Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEs — 471; 478; 343; 348 participants
Suicide
Primary: Number of Participants Who Repoorted a Suicide Event — 8; 8 participants — p=.87
Gout
Primary: BMI — 33.4 kg/m^2
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 79.85 ng/mL
Angelman Syndrome
Primary: Bayley Cognitive Age Equivalent at 1 Year — 19; 19 months — p=0.75
Colorectal Cancer
Primary: Progression-free Survival — 8.3 months
Head and Neck Cancer
Primary: Mean Change in Quality of Life as Measured by the Subscale MDASI-HN Score. — 4.3 units on a scale
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Aging
Primary: Total Number of Goals Improved to Criterion on the Canadian Occupational Performance Measure (COPM) — 50; 19.6; 50; 32.6 percentage of untrained goals improved — p=0.03
Presbyopia
Primary: The Total Grade of Conjunctival Hyperemia — 4.25; 3.72; 3.51; 3.42 units on a scale
End Stage Liver Disease · Hepatitis C
Primary: Freedom From Acute Rejection or HCV Recurrence or Treatment Failure — 69; 70; 133 participants
Ketamine-Induced Brain Activity Changes · Psychotic-like Symptoms
Primary: Ketamine-Induced Brain Activity in Regions of Interest During Resting State — 0.4954; 0.2943; 0.4439; 0.3876 percent signal change in brain activity — p=0.259
Smoking Cessation · Acute Coronary Syndrome
Primary: Smoking Cessation: 7 Day Point Prevalence Abstinence — 0.46; 0.44 proportion of participants